ホーム>>Signaling Pathways>> Others>>CS476 (NSC302998)

CS476 (NSC302998) (Synonyms: NSC302998)

カタログ番号GC32638

CS476 (NSC302998) は強力な血糖降下薬です。

Products are for research use only. Not for human use. We do not sell to patients.

CS476 (NSC302998) 化学構造

Cas No.: 41177-35-9

サイズ 価格 在庫数 個数
1mg
$809.00
在庫あり
5mg
$1,609.00
在庫あり
10mg
$2,794.00
在庫あり
20mg
$4,890.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CS476 is a potent hypoglycaemic agent.

In normal fasting dogs, rabbits, rats and mice the maximal hypoglycaemia produced by intravenous administration of CS476 is comparable on a weight basis to that produced by Glibenclamide. Randomized Latin square experiments in dogs show that 0.03 mg/kg orally of CS476 and of Glibenclamide cause the same maximal decrease of blood glucose and that CS476 has the shorter duration of action. CS476 has no hypoglycaemic effect in totally pancreatectomized dogs nor in streptozotocin diabetic dogs and rats. The insulin releasing activity is studied in dogs after intravenous and oral administration of equipotent doses of CS476, Tolbutamide and Glibenclamide[1].

[1]. Jorgensen KD. The pharmacology of a new hypoglycaemic agent N-[4-(2-(2,3-dihydrobenzo(b)furan-m-carboxamido)-ethyl)-benzenesulphonyl]-N'-cyclohexylurea (NOVO CS 476). I. Pharmacological studies on the hypoglycaemic effect. Acta Pharmacol Toxicol (Copenh). 1977 Feb;40(2):216-26.

レビュー

Review for CS476 (NSC302998)

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CS476 (NSC302998)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.